The US Food and Drug Administration has approved Gazyva/Gazyvaro (obinutuzumab) for the treatment of adults with primary membranous nephropathy (pMN) at risk of disease progression.
pMN is a chronic autoimmune kidney disease characterized by inflammation of the structures inside the kidney that help filter wastes and fluids. When the glomerular basement membrane becomes thickened, it does not work normally, allowing large amounts of protein to be lost in the urine. Symptoms develop gradually and may include swelling, fatigue, weight gain, and high blood pressure. In many cases, the underlying cause is unknown. Some cases are associated with other conditions (lupus), infections (hepatitis B and C), cancer or as a side effect of certain medications.
Obinutuzumab is a humanized monoclonal antibody designed with a Type II anti-CD20 region for direct B cell death, and a glycoengineered Fc region for higher binding affinity and increased antibody-dependent cellular cytotoxicity (ADCC). It is the first and only FDA approved therapy for pMN.
The approval is based on positive results from the phase III MAJESTY clinical trial (NCT04629248). Data from MAJESTY was featured at the 63rd European Renal Association (ERA) Congress in June 2026 as a late-breaking oral presentation and published in the New England Journal of Medicine.
The trial met its primary endpoint, with 36.1% of adults achieving complete remission (CR) of proteinuria at two years with obinutuzumab versus 5.7% with tacrolimus. Key secondary endpoints showed that obinutuzumab was superior to tacrolimus in achieving overall remission (complete or partial remission) at week 104 (50% versus 12.9%) and complete remission at week 76 (36.1% versus 8.6%.
Safety was consistent with the well-characterized profile of obinutuzumab and no new safety signals were identified.
For more information, visit https://www.roche.com/investors/updates/inv-update-2026-11-16
To learn more about pMN and other rare kidney conditions, visit https://checkrare.com/diseases/kidney-and-urinary-diseases/
Tags: autoimmune, kidney, treatment, regulations
